A case of capecitabine-induced coronary microspasm in a patient with rectal cancer

5-Fluorouracil （5-FU） is the most frequently used chemotherapy agent concomitant with radiotherapy in the management of patients with rectal cancer. Capecitabine is an oral fluoropyrimidine that mimics the pharmaconkinetics of infusional 5-FU. This new drug is replacing 5-FU as a part of the combined-modality treatment of a number of gastrointestinal cancers. While cardiac events associated with the use of 5-FU are a well known side effect, capecitabine-induced cardiotoxicity has been only rarely reported. Here, we reviewed the case of a patient with rectal cancer who had a capecitabine-induced coronary vasospasm. The most prominent mutation of the dihydropyrimidine dehydrogenase gene was also analyzed.

5 氟尿嘧啶(5-FU ) 是有在有直肠的癌症的病人的管理的放射疗法的最经常使用的化疗代理人伴随物。Capecitabine 是模仿 infusional 5-FU 的 pharmaconkinetics 的口头的 fluoropyrimidine。这新药作为很多胃肠的癌症的联合形式的治疗的部分正在代替 5-FU。当与 5-FU 的使用联系的心脏的事件是一个众所周知的副作用时，导致 capecitabine 的 cardiotoxicity 仅仅很少被报导了。这里，我们与直肠的癌症考察了一个病人的案例有导致 capecitabine 的冠的血管痉挛。dihydropyrimidine 脱氢酶基因的最突出的变化也被分析。